Global Health
Authors
News Type
News
Date
Paragraphs
The study provides evidence that a country’s ability to reduce the gap in child-mortality rates is related to good governance.

The child-mortality gap has narrowed between the poorest and wealthiest households in a majority of more than 50 developing countries, a new study from the Stanford University School of Medicine has found.

This convergence was mostly driven by the fact that child-mortality rates declined the fastest among the poorest families. In the countries where the gap increased, the study identified a common thread: poor governance.

The findings provide important information for making decisions about prioritizing global health investments to effectively promote equity, said Eran Bendavid, MD, assistant professor of medicine, core faculty member at CHP/PCOR, and the study’s author.

The study, published online Nov. 10 in Pediatrics, analyzed data from nearly 1 million families living in 54 low- and middle-income countries to determine the relationship between mortality in children under the age of 5 and wealth inequality.

“In many countries, national wealth has increased hand-in-hand with increasing health inequality. That’s been a signature of our time,” Bendavid said. “It’s a pressing concern for many societies, especially in wealthy countries, but it’s also been an issue in low- and middle-income countries.”

Assessing child mortality within developing countries

Many studies have assessed the national child mortality trends in developing countries, but they say little about the mortality gap between the poorest and wealthiest within those countries. National trends could be associated with either narrowing or widening gaps between the poorest and wealthiest populations, Bendavid noted. For example, if child mortality decreases faster among the wealthy compared with the poor, the overall child-mortality rate in that country could decrease even as the mortality gap widens. Alternatively, if child mortality decreases faster among the poor, the health gap could narrow.

To fill this gap in knowledge, the study sought to understand whether developing countries are experiencing a widening or narrowing mortality-rate gap among children under 5 of the poorest and wealthiest families.

To compare wealth status and under-5 child mortality within a country, Bendavid used data from the demographic and health surveys for 1.2 million women living in 929,224 households in 54 developing countries. The women provided information about their children’s survival status. 

 “The people who conduct these surveys, they’re intrepid surveyors,” said Bendavid, who is also a core faculty member of Stanford Health Policy, which is part of the Freeman Spogli Institute for International Studies. “They reach remote villages up the Congo basin and in the Sahel in Niger, and track the heads of households and women for these in-depth interviews.”

The surveys include information about each woman’s birth histories, including detailed birth registries documenting millions of children. With this information, Bendavid could estimate the probability of a child dying before reaching age 5 per 1,000 live births.

Tallying household possessions

Determining each household’s wealth status was not as straightforward as reviewing annual income and tax returns, which don’t exist in the countries involved in the study. “These surveys tally the possessions in the household. What is the floor made of? What is the roof made of?” Bendavid said. “You can get a wide distribution of household possessions that reflects to a large degree the household wealth.”

Next, Bendavid developed a three-tier wealth index using the household assets. The three wealth categories were relative — poorest, middle and wealthiest.

To analyze trends in wealth status and under-5 mortality, Bendavid looked at all developing countries that had completed the surveys in two specific time frames: 2002-07 and 2008-12. The study found that the under-5 mortality rates among the poorest groups had decreased the most rapidly. The average decline was 4.36 deaths each year per 1,000 live births among the poorest, 3.36 among the middle and 2.06 among the wealthiest. Because the poorest group’s mortality rate is decreasing more quickly that the other groups, the gap in child-mortality rates is closing.

This is good news, Bendavid said. However, not all countries followed this same trend. In a quarter of the surveys examined by the study, inequality in under-5 mortality increased over time.

Bendavid found that four factors were present in countries with a narrowing child-mortality gap: government effectiveness, rule of law, control of corruption and regulatory quality. He found that the difference in mortality rates was significantly associated with the governance score: Better governance scores were related to greater convergence in mortality rates among the three wealth groups.

Benefits from controlling communicable diseases

Bendavid said the evidence in this study is consistent with gains in controlling communicable diseases, such as malaria, measles, diarrhea and respiratory illnesses, that preferentially affect the poorest. Over the past decade, international health aid organizations have financed interventions for these diseases at a high rate.

It makes a persuasive case that these improvements have often begun to benefit the poor even more than the better-off.

“Dr. Bendavid’s study is an important contribution to knowledge about child health improvements in the developing world,” said Davidson Gwatkin, a senior fellow at the Results for Development Institute and a senior associate at Johns Hopkins Bloomberg School of Public Health. “It makes a persuasive case that these improvements have often begun to benefit the poor even more than the better-off.” Gwatkin was not involved in the study.

The study also raises questions about the role of foreign aid institutions in low- and middle-income countries. While the aid efforts are making a difference in child-mortality rates in countries with effective governments, the study seems to show that this is not the case in nations with poor governance, Bendavid said.

“We have the technologies, we have the means, we have the know-how to reduce child mortality dramatically,” said Bendavid. “Even for such low-hanging fruit, however, implementation is not always easy. You have to have government that enables basic safety, and the ability to reach poor and rural communities that benefit from these kinds of programs.”

This work was supported by the National Institute of Allergy and Infectious Diseases (grant KOIAI084582), the Doris Duke Charitable Foundation and the Dr. George Rosenkranz Prize for Health Care Research in Developing Countries.

 Information about Stanford’s Department of Medicine, which also supported this research, is available at http://medicine.stanford.edu.

 

Hero Image
image img  full  high
All News button
1
Paragraphs

In response to the current outbreak, the international community has endorsed the clinical use of unregistered treatments for Ebola. Even with this accelerated pathway to in-human testing and use, radically novel approaches to drug development will be needed to improve the likelihood that a treatment is realised. Bypassing steps in development does not alter the probability of success, and historical patterns in drug development suggest that there is a slim probability of success with the current portfolio of potential Ebola treatments (all of which are were in preclinical development prior to the outbreak)....

All Publications button
1
Publication Type
Journal Articles
Publication Date
Journal Publisher
The Lancet Global Health
Authors
Authors
News Type
Commentary
Date
Paragraphs

Traditional drug repurposing, although successful in treating some diseases, still requires considerable time to identify candidate compounds and even more time to test them in clinical trials. Ebola requires and deserves a much more aggressive approach, while still balancing safety and efficacy concerns.

One way to considerably speed up the drug development process is to use high-end, bioinformatics-oriented computing approaches. When applied to drug repurposing, this approach can allow for a much faster identification of candidate compounds. When applied to clinical trials, this approach may quickly provide valuable animal and human information without the need for actual subjects.

With bioinformatics, drug repurposing can be used quickly without resorting to desperate measures that compromise safety. These bioinformatics approaches are already under development for diseases that are prevalent in wealthy countries, like cancer; Ebola provides an opportunity for this potentially game-changing approach to be applied to a disease primarily affecting those in resource-limited countries.

All News button
1
Paragraphs

Context  The effect of global health initiatives on population health is uncertain. Between 2003 and 2008, the US President's Emergency Plan for AIDS Relief (PEPFAR), the largest initiative ever devoted to a single disease, operated intensively in 12 African focus countries. The initiative's effect on all-cause adult mortality is unknown.

Objective  To determine whether PEPFAR was associated with relative changes in adult mortality in the countries and districts where it operated most intensively.

Design, Setting, and Participants  Using person-level data from the Demographic and Health Surveys, we conducted cross-country and within-country analyses of adult mortality (annual probability of death per 1000 adults between 15 and 59 years old) and PEPFAR's activities. Across countries, we compared adult mortality in 9 African focus countries (Ethiopia, Kenya, Mozambique, Namibia, Nigeria, Rwanda, Tanzania, Uganda, and Zambia) with 18 African nonfocus countries from 1998 to 2008. We performed subnational analyses using information on PEPFAR's programmatic intensity in Tanzania and Rwanda. We employed difference-in-difference analyses with fixed effects for countries and years as well as personal and time-varying area characteristics.

Main Outcome Measure  Adult all-cause mortality.

Results  We analyzed information on 1 538 612 adults, including 60 303 deaths, from 41 surveys in 27 countries, 9 of them focus countries. In 2003, age-adjusted adult mortality was 8.3 per 1000 adults in the focus countries (95% CI, 8.0-8.6) and 8.5 per 1000 adults (95% CI, 8.3-8.7) in the nonfocus countries. In 2008, mortality was 4.1 per 1000 (95% CI, 3.6-4.6) in the focus countries and 6.9 per 1000 (95% CI, 6.3-7.5) in the nonfocus countries. The adjusted odds ratio of mortality among adults living in focus countries compared with nonfocus countries between 2004 and 2008 was 0.84 (95% CI, 0.72-0.99; P = .03). Within Tanzania and Rwanda, the adjusted odds ratio of mortality for adults living in districts where PEPFAR operated more intensively was 0.83 (95% CI, 0.72-0.97; P = .02) and 0.75 (95% CI, 0.56-0.99; P = .04), respectively, compared with districts where it operated less intensively.

Conclusions  Between 2004 and 2008, all-cause adult mortality declined more in PEPFAR focus countries relative to nonfocus countries. It was not possible to determine whether PEPFAR was associated with mortality effects separate from reductions in HIV-specific deaths.

All Publications button
1
Publication Type
Journal Articles
Publication Date
Journal Publisher
Journal of the American Medical Association
Authors
Eran Bendavid
Grant Miller

Y2E2
473 Via Ortega
Stanford, CA 94305

(650) 723-4129 (650) 725-3402
0
Faculty Lead, Center for Human and Planetary Health
Professor of Medicine (Infectious Diseases)
Professor of Epidemiology & Population Health (by courtesy)
Senior Fellow at the Freeman Spogli Institute for International Studies
Senior Fellow at the Woods Institute for the Environment
Faculty Affiliate at the Stanford Center on China's Economy and Institutions
steve_luby_2023-2_vert.jpg MD

Prof. Stephen Luby studied philosophy and earned a Bachelor of Arts summa cum laude from Creighton University. He then earned his medical degree from the University of Texas Southwestern Medical School at Dallas and completed his residency in internal medicine at the University of Rochester-Strong Memorial Hospital. He studied epidemiology and preventive medicine at the Centers for Disease Control and Prevention.

Prof. Luby's former positions include leading the Epidemiology Unit of the Community Health Sciences Department at the Aga Khan University in Karachi, Pakistan, for five years and working as a Medical Epidemiologist in the Foodborne and Diarrheal Diseases Branch of the U.S. Centers for Disease Control and Prevention (CDC) exploring causes and prevention of diarrheal disease in settings where diarrhea is a leading cause of childhood death.  Immediately prior to joining the Stanford faculty, Prof. Luby served for eight years at the International Centre for Diarrhoeal Diseases Research, Bangladesh (icddr,b), where he directed the Centre for Communicable Diseases. He was also the Country Director for CDC in Bangladesh.

During his over 25 years of public health work in low-income countries, Prof. Luby frequently encountered political and governance difficulties undermining efforts to improve public health. His work within the Center on Democracy, Development, and the Rule of Law (CDDRL) connects him with a community of scholars who provide ideas and approaches to understand and address these critical barriers.

 

Director of Research, Stanford Center for Innovation in Global Health
Affiliated faculty at the Center on Democracy, Development and the Rule of Law
CV
Date Label

Encina Commons Room 210,
615 Crothers Way,
Stanford, CA 94305-6006

(650) 723-1919
0
Professor, Pediatrics
Professor, Health Policy
Professor, Epidemiology & Population Health (by courtesy)
sanders_photo_20153.jpg MD, MPH

Dr. Lee Sanders is a general pediatrician and Professor of Pediatrics at the Stanford University School of Medicine, where he is Chief of the Division of General Pediatrics. He holds a joint appointment in the Center for Health Policy in the Freeman Spogli Institute for International Studies, where he is a co-director of the Center for Policy, Outcomes and Prevention (CPOP).

An author of numerous peer-reviewed articles addressing child health disparities, Dr. Sanders is a nationally recognized scholar in the fields of health literacy and child chronic-illness care.  Dr. Sanders was named a Robert Wood Johnson Foundation Generalist Physician Faculty Scholar for his leadership on the role of maternal health literacy and English-language proficiency in addressing child health disparities.  Aiming to make the US health system more navigable for the one in 4 families with limited health literacy, he has served as an advisor to the Institute of Medicine, the Centers for Disease Control and Prevention, the Food and Drug Administration, the American Academy of Pediatrics, the Academic Pediatric Association, and the American Cancer Society.  Dr. Sanders leads a multi-disciplinary CPOP research team that provides analytic guidance to national and state policies affecting children with complex chronic illness – with a focus on the special health-system requirements that arise from the unique epidemiology, care-use patterns, and health-care costs for this population.  He leads another CPOP/PCOR-based research team that applies family-centered approaches to new technologies that aim to improve care coordination for children with medical complexity.    Dr. Sanders is also principal investigator on two NIH-funded studies that address health literacy in the pediatric context: one aims to assess the efficacy of a low-literacy, early-childhood intervention designed to prevent early childhood obesity; the other aims to provide the FDA with guidance on improved labeling of pediatric liquid medication.  Research settings for this work include state and regional health departments, primary-care and subspecialty-care clinics, community-health centers, WIC offices, federally subsidized child-care centers, and family advocacy centers.

Dr. Sanders received a BA in History and Science from Harvard University, an MD from Stanford University, and a MPH from the University of California, Berkeley.  Between 2006 and 2011, Dr. Sanders served as Medical Director of Children’s Medical Services South Florida, a Florida state agency that coordinates care for more than 10,000 low-income children with special health care needs.  He was also Medical Director for Reach Out and Read Florida, a pediatric-clinic-based program that provides books and early-literacy promotion to more than 200,000 underserved children.  At the University of Miami, Dr. Sanders directed the Jay Weiss Center for Social Medicine and Health Equity, which fosters a scholarly community committed to addressing global health inequities through community-based participatory research.  At Stanford University, Dr. Sanders served as co-medical director of the Family Advocacy Program, which provides free legal assistance to help address social determinants of child health.

Fluent in Spanish, Dr. Sanders is co-director of the Complex Primary Care Clinic at Stanford Children’s Health, which provides multi-disciplinary team care for children with complex chronic conditions.  Dr. Sanders is also the father of two daughters, aged 11 and 14 years, who make sure he practices talking less and listening more.

Co-Director, Center for Policy, Outcomes & Prevention (CPOP)
Chief, Division of General Pediatrics, School of Medicine
CV
Date Label
Subscribe to Global Health